---
layout: post
title: New Drug Approvals 2011 - Pt. XIII Linagliptin (TradjentaTM)
date: '2011-05-17T13:41:00.012+01:00'
author: Ben
tags:
- 2011 New Drugs
- Small Molecule Drugs
modified_time: '2012-01-04T09:23:45.574Z'
thumbnail: http://2.bp.blogspot.com/-Jm7Zf2s-Ja0/TdJpYVxM8oI/AAAAAAAAACI/Dgi6kaJ6bv0/s72-c/tradjenta-AP%25282%2529_244x183.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-3084355788777057492
blogger_orig_url: http://chembl.blogspot.com/2011/05/new-drug-approvals-2011-pt-xiii.html
---

<span style="font-size: small;"><a href="http://2.bp.blogspot.com/-Jm7Zf2s-Ja0/TdJpYVxM8oI/AAAAAAAAACI/Dgi6kaJ6bv0/s1600/tradjenta-AP%25282%2529_244x183.jpg"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5607660352910979714" src="http://2.bp.blogspot.com/-Jm7Zf2s-Ja0/TdJpYVxM8oI/AAAAAAAAACI/Dgi6kaJ6bv0/s200/tradjenta-AP%25282%2529_244x183.jpg" style="cursor: pointer; display: block; height: 150px; margin: 0px auto 10px; text-align: center; width: 200px;" /></a></span>
<br />
<br />
<center style="font-family: arial;"><span style="font-size: small;">  <img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,1,0,0,1,0,0" width="400" /></span></center> <b><span class="Apple-style-span" style="font-weight: normal;">
</span></b><br />
<div style="font-family: arial; text-align: center;">
<span style="font-size: small; font-weight: bold;">ATC code :</span><span style="font-size: small;"> <a href="http://www.whocc.no/atc_ddd_index/?code=A10BH05">A10BH05</a>   </span>

<br />
<div style="text-align: justify;">
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">On  May 2<sup>nd</sup>, the FDA approved Linagliptin (BI-1356, trade name <a href="http://www.trademarkia.com/tradjenta-85223216.html">Tradjenta</a>, ATC code <a href="http://www.whocc.no/atc_ddd_index/?code=A10BH05">A10BH05</a>, ChEMBL ID <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL237500">237500</a>&nbsp;NDA 201280), a dipeptidyl peptidase-4 (DPP-4) inhibitor, to treat type II diabetes (OMIM: <a href="http://www.ncbi.nlm.nih.gov/omim/125853">125853</a>). Linagliptin has been approved for monotherapy or in combination with other medications, in conjunction with exercise and dietary modification. Due to a malfunction in production of or response to insulin, patients with type II diabetes suffer from high blood glucose levels.</span><br />
<span style="font-size: small;"><br /></span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">
</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">
</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"> </span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"> </span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">By inhibiting DPP-4 (Uniprot <a href="http://www.uniprot.org/uniprot/P27487">P27487</a>, OMIM: <a href="http://www.ncbi.nlm.nih.gov/omim/102720">102720</a>, EC number 3.4.14.5), a cell surface glycoprotein receptor, Linagliptin stabilizes the level of two of its substrates, the intecrins GLP-1 and GIP, gastrointestinal peptide hormones which stimulate insulin release from beta cells of the <a href="http://en.wikipedia.org/wiki/Islets_of_Langerhans">Islets of Langerhans</a>.</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span class="Apple-style-span" style="font-size: small;">
</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span class="Apple-style-span" style="font-size: small;">
</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span class="Apple-style-span" style="font-size: small;"><br /></span><br />
<span style="font-size: small;"></span><span class="Apple-style-span" style="font-size: small;">Linagliptin <a href="https://www.ebi.ac.uk/chembldb/index.php/doc/inspect/CHEMBL1138349">has been shown</a> to have a high affinity (Ki 1 nM) for DPP-4 in cell-based fluorescence assays, <a href="http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&amp;p_RefId=1215244&amp;p_IsPs=N">and to be</a> highly selective. </span><span class="Apple-style-span" style="font-size: small;">DPP-4 exists in soluble form (aminoacids 39-766) or with a N-terminal single-anchor domain, linking the extracellular domain to the cell membrane. There are several homodimeric crystal structures available, e.g. <a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1j2e/summary">PDB 1J2E</a>.</span></div>
<div class="MsoNormal" style="text-align: justify;">
<a href="http://1.bp.blogspot.com/-2RsUxyDY1rY/TdJqrpx-v1I/AAAAAAAAACY/JM02kx_raxA/s1600/PDB_1j2e_EBI.jpg"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5607661784212094802" src="http://1.bp.blogspot.com/-2RsUxyDY1rY/TdJqrpx-v1I/AAAAAAAAACY/JM02kx_raxA/s400/PDB_1j2e_EBI.jpg" style="display: block; height: 300px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; text-align: center; width: 400px;" /></a>The -gliptin USAN stem covers DPP-IV inhibitors, and there are a number already launched (<i>e.g</i>. <a href="http://en.wikipedia.org/wiki/Saxagliptin">Saxagliptin</a>, <a href="http://en.wikipedia.org/wiki/Sitagliptin">Sitagliptin</a> and <a href="http://en.wikipedia.org/wiki/Vildagliptin">Vildagliptin</a>) and many others in clinical trials/registration (<i>e.g</i>. <a href="http://en.wikipedia.org/wiki/Alogliptin">Alogliptin</a> (SYR-322, TAK-322), Carmegliptin (R-1579, Ro-4876904), Dutogliptin (PHX-1149), Gosogliptin (PF-734200), and Denagliptin (GSK-823903)). There are a very large number of others at earlier stages of development include R-1438, BI-1356, NVP-DPP-728, GRC-8200, SK-0403, P-32/98, PSN-9301, TS-021, R-1499, PSN-357, DP-893, LC-150444, BMS-686117, TAK-100, BMS-477128, ABT-279, ARI-2243, SSR-162339, ER-319711 Ro-0730699, NN-7201, MP-513, KRP-104, E-3024, and ALS-2-0426 (AMG-222).<br />
<br /></div>
<div class="MsoNormal" style="text-align: justify;">
</div>
<div class="MsoNormal" style="text-align: justify;">
</div>
<div class="MsoNormal" style="text-align: justify;">
There is a previous ChEMBL-og monograph available for <a href="http://chembl.blogspot.com/2009/08/new-drug-approvals-pt-xii-saxagliptin.html">Saxagliptin</a>.
<span class="Apple-style-span" style="font-size: small;"></span>
</div>
<div class="MsoNormal" style="text-align: justify;">
<span class="Apple-style-span" style="font-size: small;"><br /></span><br />
<span class="Apple-style-span" style="font-size: small;">Linagliptin (systematic name 8-[(3<i>R</i>)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1<i>H</i>-purine-2,6-dione) has the chemical formula C25H28N8O2, molecular mass of 472.54 g/mol. ), AlogP of 2.1 and is fully Rule-of-five compliant.</span></div>
<div class="MsoNormal" style="text-align: justify;">
</div>
<div class="MsoNormal" style="text-align: justify;">
<span class="Apple-style-span" style="font-size: small;"></span>Smiles=CC#CCn1c(nc2N(C)C(=O)N(Cc3nc(C)c4ccccc4n3)C(=O)c12)N5CCC[C@@H](N)C5</div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">;</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1.</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">
</span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-N2U1DgANhPo/TdJsijojApI/AAAAAAAABJM/ct9wWIwLGaQ/s1600/800px-Linagliptin.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="156" src="http://2.bp.blogspot.com/-N2U1DgANhPo/TdJsijojApI/AAAAAAAABJM/ct9wWIwLGaQ/s320/800px-Linagliptin.png" width="320" /></a></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">

</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"><br /></span><br />
<span style="font-size: small;">Tradjenta is dosed as a 5 mg tablet, once daily (equivalent to a daily dose of 10.6 umol).</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"> </span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"> </span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">After a single administration, a maximum concentration (C<sub>max</sub>) of  8.9 nmol/L is reached after T<sub>max</sub>=1.5 h. Linagliptin has a long terminal half-life (&gt;100 h) and steady-state plasma concentrations are reached after the third daily dose. At steady state, C<sub>max</sub> is increased by a factor of ~1.3 as compared to the single administration. The mean apparent volume of distribution (Vd) is approximately 1110 L. </span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">
</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"><br /></span><br />
<span style="font-size: small;">
Tradjenta is distributed by <a href="http://www.boehringer-ingelheim.com/">Boehringer Ingelheim</a> and marketed by Boehringer Ingelheim and <a href="http://www.lilly.com/">Eli Lilly and Company</a>. In Europe the tradename is Trajenta.</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;">

</span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"> </span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"> </span></div>
<div class="MsoNormal" style="text-align: justify;">
<span style="font-size: small;"><br /></span><br />
<span style="font-size: small;">The full prescribing information can be found <a href="http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing+Information/PIs/Tradjenta/Tradjenta.pdf">here</a> and the product website, <a href="http://www.tradjenta.com/">here</a>. </span></div>
</div>
</div>